WO2011021676A1 - ベンゾ［ｂ］［１，４］ジアゼピン－２，４－ジオン化合物の製造方法 - Google Patents

ベンゾ［ｂ］［１，４］ジアゼピン－２，４－ジオン化合物の製造方法 Download PDF

Info

Publication number
WO2011021676A1
WO2011021676A1 PCT/JP2010/064040 JP2010064040W WO2011021676A1 WO 2011021676 A1 WO2011021676 A1 WO 2011021676A1 JP 2010064040 W JP2010064040 W JP 2010064040W WO 2011021676 A1 WO2011021676 A1 WO 2011021676A1
Authority
WO
WIPO (PCT)
Prior art keywords
general formula
reaction
compound represented
compound
mol
Prior art date
Application number
PCT/JP2010/064040
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
久元 辻森
伸一 平良
浩孝 湯川
阿部　薫
Original Assignee
大塚製薬株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大塚製薬株式会社 filed Critical 大塚製薬株式会社
Priority to CA2771136A priority Critical patent/CA2771136A1/en
Priority to BR112012003871A priority patent/BR112012003871A2/pt
Priority to US13/391,468 priority patent/US8796447B2/en
Priority to RU2012110566/04A priority patent/RU2553676C2/ru
Priority to CN201080037096.9A priority patent/CN102639512B/zh
Priority to IN986DEN2012 priority patent/IN2012DN00986A/en
Priority to JP2011527709A priority patent/JP5649577B2/ja
Priority to EP10810017A priority patent/EP2468733A4/en
Publication of WO2011021676A1 publication Critical patent/WO2011021676A1/ja
Priority to IL217855A priority patent/IL217855A/en
Priority to US14/202,793 priority patent/US8940889B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention relates to a method for producing a benzo [b] [1,4] diazepine-2,4-dione compound useful as a production intermediate for pharmaceuticals and the like, and a raw material compound used in the production method.
  • Atrial fibrillation (hereinafter referred to as “AF”) is the most commonly observed arrhythmia in clinical practice. Although AF is not a lethal arrhythmia, it has been recognized as an arrhythmia that has a great impact on life prognosis and QOL because it causes cardiogenic cerebral embolism. It is known that the onset of AF increases with aging, and AF becomes chronic (severe) by repeating seizures (Non-patent Documents 1 and 2).
  • Non-patent Document 3 Non-patent Document 3
  • Non-patent Document 4 It is known that atrial fibrillation can be stopped (defibrillation) or prevented from occurring by extending the refractory period of the atrial muscle.
  • the action potential duration of mammalian myocardium is mainly determined by voltage-dependent K + channels. It is known that inhibition of the K + channel prolongs the action potential duration of the myocardium and, as a result, prolongs the refractory period (Non-patent Document 5).
  • class III antiarrhythmic drugs eg, dofetilide, etc.
  • I Kr HERG-encoded K + current
  • I Kr is present not only in the atria but also in the ventricles. Therefore, there is a risk of causing ventricular arrhythmia such as torsades de pointes (Non-Patent Document 6).
  • K + current (I Kur ) encoded by Kv1.5 has been discovered as a K + channel specifically expressed only in the human atrium (Non-patent Document 7, Non-patent Document 8 and Non-patent Document). Reference 9).
  • muscarinic K current (I KAch ) encoded by two genes, GIRK1 and GIRK4 is known as a K + channel that is specifically expressed in the atrium in humans (Non-patent Document 10).
  • the I Kur current Kv1.5 channel
  • the I KAch current GIRK1 / 4 channel
  • Patent Document 1 has not been disclosed on the filing date (August 21, 2009) of US provisional application 61/235898, which is the basis of the priority of the international patent application.
  • novel benzo [b] [1,4] diazepine-2,4-dione compound described in Patent Document 1 is useful as a therapeutic agent for arrhythmia and has the general formula (1)
  • R 1 , R 2 , R 3 and R 4 are the same or different and each represents a hydrogen atom or a lower alkyl group. ] It is manufactured via the compound (key intermediate) represented by these. Therefore, a method for producing the compound represented by the general formula (1) simply and efficiently has been desired.
  • An object of the present invention is to provide a method for producing a compound represented by the general formula (1) which is industrially advantageous and simple and efficient, and a raw material compound used in the production method.
  • the present invention provides a method for producing a benzo [b] [1,4] diazepine-2,4-dione compound shown in the following items 1 to 7, and a raw material compound used in the production method.
  • R 1 , R 2 , R 3 and R 4 are the same or different and each represents a hydrogen atom or a lower alkyl group.
  • R 1 , R 2 , R 3 and R 4 are the same as above.
  • R 5 represents a hydroxyl-protecting group.
  • Item 3. The production method according to Item 1 or 2, wherein R 5 is a benzyl group which may be substituted, and the benzyl group which may be substituted by reduction in the presence of a catalytic hydrogen reducing agent is deprotected.
  • R 1 , R 2 , R 3 and R 4 are the same or different and each represents a hydrogen atom or a lower alkyl group.
  • R 5 represents a hydroxyl-protecting group.
  • R 1 , R 2 , R 3 and R 4 are the same or different and each represents a hydrogen atom or a lower alkyl group.
  • R 5 represents a hydroxyl-protecting group.
  • R 2 , R 3 and R 4 are the same or different and each represents a hydrogen atom or a lower alkyl group.
  • R 5 represents a hydroxyl-protecting group.
  • R 2 and R 3 are the same as above.
  • X c is the same or different and represents a halogen atom.
  • the manufacturing method characterized by making the compound represented by these react.
  • a benzo [b] [1,4] diazepine-2,4-dione compound having a hydroxyl group on the benzene ring represented by the general formula (1) is industrially advantageous. It can be produced simply and efficiently.
  • the reaction for converting the compound represented by the general formula (2) into the compound represented by the general formula (1) can be performed by deprotecting the protecting group (R 5 ) in an appropriate solvent.
  • R 1 , R 2 , R 3 , R 4 and R 5 are the same as above.
  • Examples of the lower alkyl group represented by R 1 , R 2 , R 3 and R 4 include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, Examples thereof include linear or branched alkyl groups having 1 to 6 carbon atoms such as neopentyl, n-hexyl and isohexyl groups. In particular, alkyl groups having 1 to 4 carbon atoms such as methyl, ethyl, n-propyl, isopropyl, n-butyl and isobutyl groups are preferred.
  • Examples of the hydroxyl-protecting group represented by R 5 include an optionally substituted benzyl group.
  • substituent of the benzyl group examples include a lower alkyl group, a halogen atom, a cyano group, a lower alkoxy group, a nitro group, a phenyl group, and an acyl group.
  • the benzene ring of the benzyl group may be substituted with at least 1 to 5 (particularly 1 to 3) substituents selected from these.
  • the lower alkyl group can be selected from the lower alkyl groups represented by R 1 , R 2 , R 3 and R 4 described above.
  • halogen atom examples include a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom.
  • Examples of the lower alkoxy group include linear or branched alkoxy groups having 1 to 6 carbon atoms such as methoxy, ethoxy, propoxy, isopropoxy, and n-butoxy group. In particular, an alkoxy group having 1 to 4 carbon atoms is preferable.
  • Acyl groups include, for example, lower (eg 1 to 6 carbon) alkanoyl groups such as formyl, acetyl, propionyl, hexanoyl, pivaloyl groups; methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, tert-pentyloxycarbonyl, hexyl Lower (for example, C 1-6) alkoxycarbonyl groups such as oxycarbonyl group; Aroyl groups such as benzoyl, toluoyl, naphthoyl group; appropriate substitution such as benzyloxycarbonyl, phenethyloxycarbonyl, p-nitrobenzyloxycarbonyl group Examples include aryl lower (eg, having 1 to 6 carbon atoms) alkoxycarbonyl group which may be substituted with a group.
  • lower alkanoyl groups such as formyl, acetyl, propionyl, hexanoy
  • the optionally substituted benzyl group include benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, 2,6-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, chlorobenzyl, fluoro
  • examples include benzyl, 2,6-dichlorobenzyl, 2,4-dichlorobenzyl, 2,6-difluorobenzyl, p-cyanobenzyl, p-phenylbenzyl, p-acetylbenzyl group and the like.
  • the bonding position of the hydroxyl group on the benzene ring is not particularly limited, and the compound represented by the general formula (1) is represented by the following general formulas (1A) to (1D).
  • the compound is included.
  • a compound represented by the general formula (1A) or (1B) is preferable.
  • the wavy line means that the structural formula is omitted.
  • reaction formula-1A A preferred specific example of the above reaction formula-1 is the following reaction formula-1A.
  • R 1 , R 2 , R 3 , R 4 and R 5 are the same as above.
  • R 5 is a benzyl group, which is a typical example of this reaction, will be described below.
  • the reaction for converting the compound represented by the general formula (2) into the compound represented by the general formula (1) is performed by reduction (debenzylation) in the presence of a catalytic hydrogen reducing agent in an appropriate solvent. Can do.
  • the solvent is not particularly limited as long as it does not adversely affect the reduction reaction.
  • carboxylic acids such as formic acid and acetic acid
  • ethers such as dioxane, tetrahydrofuran, diethyl ether, diethylene glycol dimethyl ether, and ethylene glycol dimethyl ether
  • methanol Lower (for example, C1-6) alcohols such as ethanol and isopropanol
  • Hydrocarbons such as n-hexane and cyclohexane
  • Esters such as ethyl acetate and methyl acetate
  • Aprotic such as N, N-dimethylformamide Polar solvents
  • aromatic hydrocarbons such as benzene, toluene and xylene; or a mixed solvent thereof.
  • Preferred are alcohols having 1 to 3 carbon atoms such as methanol, ethanol and isopropanol.
  • Examples of the contact hydrogen reducing agent include palladium-black, palladium-carbon, palladium hydroxide-carbon, platinum-carbon, platinum, platinum black, platinum oxide, copper chromite, and Raney nickel.
  • the amount of the catalytic hydrogen reducing agent used is typically 0.1 to 40% by weight, preferably 1 to 20% by weight, based on the compound represented by the general formula (2).
  • the reaction can be usually performed in a hydrogen atmosphere of 1 to 20 atm, preferably 1 to 10 atm, more preferably 1 to 5 atm.
  • the reaction temperature is usually ⁇ 20 to 150 ° C., preferably 0 to 100 ° C.
  • the reaction is generally completed in about 0.5 to 100 hours.
  • an acid such as hydrochloric acid may be added to the reaction.
  • the above-mentioned predetermined protecting group (R 5 ) is employed as a protecting group for the hydroxyl group on the benzene ring. Accordingly, the hydroxyl group on the benzene ring is appropriately protected in the process leading to the production of the compound represented by the general formula (2), and then deprotected under mild conditions to obtain the compound represented by the general formula (1) Can be efficiently led to.
  • the protecting groups (R 5 ) an optionally substituted benzyl group is preferred.
  • the compound represented by the general formula (2) includes compounds represented by the following general formulas (2a) to (2i).
  • the compounds represented by the general formulas (2a) to (2i) are converted into compounds (1a) to (1i) each having a corresponding phenolic hydroxyl group by the above deprotection reaction.
  • the compounds represented by the general formulas (2a) to (2c) can be produced, for example, by the process described in the reaction formula-2.
  • R 1A , R 2A , R 3A , R 4 and R 5 are the same as above.
  • R 6 represents a lower alkyl group.
  • X A is a halogen atom.
  • X B represents a leaving group.
  • Examples of the lower alkyl group represented by R 1A , R 2A and R 3A include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, neopentyl, n -Straight or branched alkyl groups having 1 to 6 carbon atoms such as hexyl and isohexyl groups.
  • alkyl groups having 1 to 4 carbon atoms such as methyl, ethyl, n-propyl, isopropyl, n-butyl and isobutyl groups are preferred.
  • Examples of the lower alkyl group represented by R 6 include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, neopentyl, n-hexyl, isohexyl group and the like. And a linear or branched alkyl group having 1 to 6 carbon atoms. In particular, alkyl groups having 1 to 3 carbon atoms such as methyl, ethyl, and isopropyl groups are exemplified.
  • the halogen atom represented by X A fluorine atom, chlorine atom, bromine atom, and an iodine atom.
  • X A fluorine atom
  • chlorine atom chlorine atom
  • bromine atom bromine atom
  • an iodine atom Preferably it is a chlorine atom.
  • Examples of the leaving group represented by X B for example, a halogen atom (e.g., fluorine atom, chlorine atom, bromine atom, an iodine atom), an organic sulfonyloxy group (e.g., p- toluenesulfonyloxy, methanesulfonyloxy, trifluoperazine Lomethanesulfonyloxy group, nonafluorobutanesulfonyl, etc.).
  • a halogen atom e.g., fluorine atom, chlorine atom, bromine atom, an iodine atom
  • an organic sulfonyloxy group e.g., p- toluenesulfonyloxy, methanesulfonyloxy, trifluoperazine Lomethanesulfonyloxy group, nonafluorobutanesulfonyl, etc.
  • the solvent examples include water; ethers such as dioxane, tetrahydrofuran, diethyl ether, diethylene glycol dimethyl ether, and ethylene glycol dimethyl ether; lower (eg, having 1 to 6 carbon atoms) alcohols such as methanol, ethanol, and isopropanol; benzene, toluene, Aromatic hydrocarbons such as xylene; or a mixed solvent thereof.
  • Preferred are water; alcohols having 1 to 3 carbon atoms such as methanol and ethanol; aromatic hydrocarbons such as toluene and xylene; or a mixed solvent thereof.
  • the proportion of the compound represented by the general formula (3) and the compound represented by the general formula (4) is usually 0.5 to 10 mol, preferably 0.8 to 1 mol with respect to 1 mol of the former.
  • the amount may be 10 mol, more preferably 1.8 to 5.0 mol.
  • the reaction temperature of the reaction is usually ⁇ 20 to 150 ° C., preferably ⁇ 20 to 100 ° C.
  • the reaction is generally completed in about 0.5 to 10 hours.
  • the solvent examples include water; ethers such as dioxane, tetrahydrofuran, diethyl ether, diethylene glycol dimethyl ether, and ethylene glycol dimethyl ether; aromatic hydrocarbons such as benzene, toluene, and xylene; dichloromethane, dichloroethane, chloroform, carbon tetrachloride, and the like.
  • Halogenated hydrocarbons lower (eg 1 to 6 carbon) alcohols such as methanol, ethanol, isopropanol; ketones such as acetone and methyl ethyl ketone; dimethylformamide (DMF), dimethylacetamide (DMA), dimethylsulfoxide (DMSO) ), Polar solvents such as hexamethylphosphoric triamide and acetonitrile, and mixed solvents thereof.
  • lower alcohols such as methanol, ethanol, isopropanol
  • ketones such as acetone and methyl ethyl ketone
  • dimethylformamide (DMF), dimethylacetamide (DMA), dimethylsulfoxide (DMSO) dimethylsulfoxide (DMSO)
  • Polar solvents such as hexamethylphosphoric triamide and acetonitrile, and mixed solvents thereof.
  • the inorganic base examples include alkali metal hydroxides such as sodium hydroxide, potassium hydroxide, cesium hydroxide, and lithium hydroxide; sodium carbonate, potassium carbonate, cesium carbonate, lithium carbonate, lithium hydrogen carbonate, sodium hydrogen carbonate, Examples thereof include alkali metal carbonates such as potassium hydrogen carbonate; alkali metals such as sodium and potassium; alkali metal amides such as sodium amide; alkali metal hydrides such as sodium hydride and potassium hydride.
  • alkali metal hydroxides such as sodium hydroxide, potassium hydroxide, cesium hydroxide, and lithium hydroxide
  • sodium carbonate, potassium carbonate, cesium carbonate, lithium carbonate, lithium hydrogen carbonate, sodium hydrogen carbonate examples thereof include alkali metal carbonates such as potassium hydrogen carbonate; alkali metals such as sodium and potassium; alkali metal amides such as sodium amide; alkali metal hydrides such as sodium hydride and potassium hydride.
  • organic bases include alkali metal alcoholates such as sodium methoxide, sodium ethoxide, sodium tert-butoxide, potassium methoxide, potassium ethoxide, potassium tert-butoxide; triethylamine, tripropylamine, pyridine, quinoline, 1 , 5-diazabicyclo [4.3.0] nonene-5 (DBN), 1,8-diazabicyclo [5.4.0] undecene-7 (DBU), 1,4-diazabicyclo [2.2.2] octane (DABCO). These basic compounds can be used individually by 1 type or in mixture of 2 or more types.
  • alkali metal alcoholates such as sodium methoxide, sodium ethoxide, sodium tert-butoxide, potassium methoxide, potassium ethoxide, potassium tert-butoxide
  • triethylamine, tripropylamine pyridine
  • quinoline 1
  • DBN 1,8-diazabicyclo [
  • the amount of the basic compound used is usually 0.5 to 10 mol, preferably 0.5 to 6 mol, relative to 1 mol of the compound represented by the general formula (5).
  • the proportion of the compound represented by the general formula (5) and the compound represented by the general formula (6) is usually 0.5 to 10 mol, preferably 0.8 to 1 mol with respect to 1 mol of the former.
  • the amount may be 5.0 mol, more preferably 0.9 to 3.0 mol.
  • Interlayer transfer catalyst can be used to promote the reaction, and examples thereof include quaternary ammonium salts, phosphonium salts, pyridinium salts and the like.
  • Examples of the quaternary ammonium salt include, for example, a linear or branched alkyl group having 1 to 18 carbon atoms, and a phenylalkyl group in which the alkyl portion is a linear or branched alkyl group having 1 to 6 carbon atoms. And a quaternary ammonium salt in which a group selected from the group consisting of phenyl groups is bonded to a nitrogen atom.
  • the quaternary ammonium salt include tetrabutylammonium chloride, tetrabutylammonium bromide, tetrabutylammonium fluoride, tetrabutylammonium iodide, tetrabutylammonium hydroxide, tetrabutylammonium hydrogensulfite, tetrabutylammonium hydrogensulfate, Tributylmethylammonium chloride, tributylbenzylammonium chloride, tetrapentylammonium chloride, tetrapentylammonium bromide, tetrahexylammonium chloride, benzyldimethyloctylammonium chloride, methyltrihexylammonium chloride, benzyldimethyloctadecanylammonium chloride, methyltridecanylammonium Chloride, benzyltrip Pills
  • Examples of the phosphonium salt include a phosphonium salt in which a linear or branched alkyl group having 1 to 18 carbon atoms is bonded to a phosphorus atom.
  • Specific examples of the phosphonium salt include tetrabutylphosphonium chloride.
  • pyridinium salt examples include a pyridinium salt in which a linear or branched alkyl group having 1 to 18 carbon atoms is bonded to a nitrogen atom.
  • pyridinium salts include 1-dodecanylpyridinium chloride.
  • phase transfer catalysts are used singly or in combination of two or more.
  • the amount of the phase transfer catalyst used is usually 0.01 to 1 mol, preferably 0.02 to 0.5 mol, per 1 mol of the compound represented by the general formula (5).
  • the above reaction is usually performed at ⁇ 10 to 150 ° C., preferably 0 to 120 ° C., and is usually completed in 0.5 to 80 hours. If necessary, it can be converted into a salt such as hydrochloride, 1 ⁇ 2 sulfate, p-toluenesulfonate, etc., using a known salt formation method.
  • a salt such as hydrochloride, 1 ⁇ 2 sulfate, p-toluenesulfonate, etc.
  • the solvent examples include ethers such as dioxane, tetrahydrofuran, diethyl ether, diethylene glycol dimethyl ether, and ethylene glycol dimethyl ether; aromatic hydrocarbons such as benzene, toluene, and xylene; halogenated compounds such as dichloromethane, dichloroethane, chloroform, and carbon tetrachloride. Hydrocarbons; ketones such as acetone and methyl ethyl ketone; polar solvents such as dimethylformamide (DMF), dimethylacetamide (DMA), dimethyl sulfoxide (DMSO), hexamethylphosphoric triamide, acetonitrile, and mixed solvents thereof It is done.
  • Aromatic hydrocarbons such as toluene and xylene are preferred.
  • the amount of the compound represented by the general formula (8) is usually 0.5 to 2 mol, preferably 0.7 to 1.3 mol, relative to 1 mol of the compound represented by the general formula (7). More preferably, it is 0.9 to 1.2 mol.
  • the above reaction is usually carried out at 0 to 150 ° C., preferably 0 to 120 ° C., and is usually completed in 1 to 80 hours.
  • the solvent is not particularly limited as long as it does not adversely affect the reduction reaction.
  • carboxylic acids such as formic acid and acetic acid
  • ethers such as dioxane, tetrahydrofuran, diethyl ether, diethylene glycol dimethyl ether, and ethylene glycol dimethyl ether
  • methanol Lower (for example, C1-6) alcohols such as ethanol and isopropanol
  • Hydrocarbons such as n-hexane and cyclohexane
  • Esters such as ethyl acetate and methyl acetate
  • Aprotic such as N, N-dimethylformamide Polar solvents
  • aromatic hydrocarbons such as benzene, toluene and xylene; or a mixed solvent thereof.
  • Preferred are alcohols having 1 to 3 carbon atoms such as methanol, ethanol and isopropanol.
  • Examples of the contact hydrogen reducing agent include palladium-black, palladium-carbon, palladium hydroxide-carbon, platinum-carbon, platinum, platinum black, platinum oxide, copper chromite, and Raney nickel.
  • the amount of the catalytic hydrogen reducing agent used is typically 0.1 to 40% by weight, preferably 1 to 20% by weight, based on the compound represented by the general formula (9).
  • a substance that is, a poisoning substance
  • the poisoning substance include sulfides such as diphenyl sulfide and dimethyl sulfide; dipyridyl, ethylenediamine and the like. Diphenyl sulfide is preferred.
  • the amount used is typically 0.0001 to 0.2 mol, preferably 0.001 with respect to 1 mol of the compound represented by the general formula (9). Mol to 0.1 mol.
  • the reaction can be usually carried out in a hydrogen atmosphere of 0.5 to 20 atm, preferably 1 to 10 atm, more preferably 1 to 5 atm.
  • the reaction temperature is usually ⁇ 20 to 50 ° C., preferably ⁇ 10 to 40 ° C.
  • the reaction is generally completed in about 0.5 to 100 hours.
  • the compound represented by the general formula (9a) can be subjected to the next ring closure reaction as a crude product.
  • the solvent is not particularly limited as long as it does not adversely affect the ring closure reaction.
  • ethers such as dioxane, tetrahydrofuran, diethyl ether, diethylene glycol dimethyl ether, and ethylene glycol dimethyl ether; aromatic carbonization such as benzene, toluene, and xylene
  • aromatic carbonization such as benzene, toluene, and xylene
  • examples thereof include hydrogens; esters such as ethyl acetate and methyl acetate; aprotic polar solvents such as N, N-dimethylformamide; and mixed solvents thereof.
  • Aromatic hydrocarbons such as toluene and xylene are preferred.
  • the inorganic base examples include alkali metal hydroxides such as sodium hydroxide, potassium hydroxide, cesium hydroxide, and lithium hydroxide; sodium carbonate, potassium carbonate, cesium carbonate, lithium carbonate, lithium hydrogen carbonate, sodium hydrogen carbonate, Examples include alkali metal carbonates such as potassium hydrogen carbonate; alkali metals such as sodium and potassium; sodium amide, sodium hydride, potassium hydride, potassium bistrimethylsilylamide, and the like.
  • organic bases include alkali metal alcoholates such as sodium methoxide, sodium ethoxide, sodium tert-butoxide, potassium methoxide, potassium ethoxide, potassium tert-butoxide; triethylamine, tripropylamine, pyridine, quinoline, 1 , 5-diazabicyclo [4.3.0] nonene-5 (DBN), 1,8-diazabicyclo [5.4.0] undecene-7 (DBU), 1,4-diazabicyclo [2.2.2] octane (DABCO). These basic compounds can be used individually by 1 type or in mixture of 2 or more types.
  • alkali metal alcoholates such as sodium methoxide, sodium ethoxide, sodium tert-butoxide, potassium methoxide, potassium ethoxide, potassium tert-butoxide
  • triethylamine, tripropylamine pyridine
  • quinoline 1
  • DBN 1,8-diazabicyclo [
  • the amount of the basic compound used is usually 0.001 to 10 mol, preferably 0.2 to 2 mol, relative to 1 mol of the compound represented by the general formula (9a).
  • the amount of the basic compound used is usually 0 with respect to 1 mol of compound (9a).
  • the catalyst amount may be about 1 to 0.8 mol.
  • the inert solvent examples include water; ethers such as dioxane, tetrahydrofuran, diethyl ether, diethylene glycol dimethyl ether, and ethylene glycol dimethyl ether; aromatic hydrocarbons such as benzene, toluene, and xylene; dichloromethane, dichloroethane, chloroform, and carbon tetrachloride.
  • Halogenated hydrocarbons such as: lower alcohols such as methanol, ethanol, isopropanol, etc.
  • ketones such as acetone, methyl ethyl ketone; dimethylformamide (DMF), dimethylacetamide (DMA), dimethyl sulfoxide (DMSO), a polar solvent such as hexamethylphosphoric triamide, acetonitrile, or a mixed solvent thereof can be used.
  • ketones such as acetone, methyl ethyl ketone; dimethylformamide (DMF), dimethylacetamide (DMA), dimethyl sulfoxide (DMSO), a polar solvent such as hexamethylphosphoric triamide, acetonitrile, or a mixed solvent thereof can be used.
  • DMF dimethylformamide
  • DMA dimethylacetamide
  • DMSO dimethyl sulfoxide
  • a polar solvent such as hexamethylphosphoric triamide, acetonitrile, or a mixed solvent thereof
  • alkali metal hydroxides such as sodium hydroxide, potassium hydroxide, cesium hydroxide, lithium hydroxide
  • Alkali metal carbonates such as lithium hydrogen carbonate, sodium hydrogen carbonate and potassium hydrogen carbonate
  • alkali metals such as sodium and potassium
  • inorganic bases such as sodium amide, sodium hydride and potassium hydride
  • Alkali metal alcoholates such as sodium tert-butoxide, potassium methoxide, potassium ethoxide, potassium tert-butoxide
  • the amount of the basic compound used is usually 0.5 to 10 mol, preferably 0.5 to 6 mol, relative to 1 mol of the compound represented by the general formula (2c).
  • the phase transfer catalyst can be used to promote the reaction.
  • the phase transfer catalyst (quaternary ammonium salt, phosphonium salt, phosphonium salt, used in the step of converting the compound (5) of the reaction formula-2 to (7) is used. Pyridinium salts, etc.) can be used.
  • the amount of the phase transfer catalyst to be used is generally 0.01-1 mol, preferably 0.01-0.5 mol, per 1 mol of compound (2c).
  • the above reaction can be carried out by adding an alkali metal iodide compound such as potassium iodide or sodium iodide into the reaction system as a reaction accelerator if necessary.
  • the amount of the alkali metal iodide compound to be used is generally 0.1 to 10 mol, preferably 0.8 to 3.0 mol, per 1 mol of compound (2c).
  • the ratio of the compound represented by the general formula (2c) and the lower alkylating agent (10) is usually at least 1 mol, preferably 1 to 1.5 mol, more preferably 1 mol with respect to 1 mol of the former. It may be 1 to 1.3 mol.
  • the above reaction is usually completed in about 0.5 to 80 hours under a temperature condition of ⁇ 20 ° C. to 100 ° C., preferably 0 ° C. to 80 ° C.
  • the lower alkyl group (R 2A ) in the lower alkylating agent (11) is different from the lower alkyl group (R 3A ) in the lower alkylating agent (12), it is represented by the general formula (2b).
  • 0.5 mol or more (especially 0.5 to 1.5 mol) of the lower alkylating agent (11) and then 1 mol or more (especially 1 to 3 mol) of the lower alkylating agent (12) with respect to 1 mol of the compound. Mol) can be reacted stepwise.
  • the lower alkyl group (R 2A ) in the lower alkylating agent (11) and the lower alkyl group (R 3A ) in the lower alkylating agent (12) are the same, the lower alkyl group (R 2A )
  • the alkylating agent (11) and / or (12) can be reacted in one step using a total of 2 mol or more (particularly 2 to 5 mol).
  • the compounds represented by the general formulas (2d) and (2e) can be produced, for example, by the process described in the reaction formula-3.
  • X C is the same or different and represents a halogen atom.
  • the halogen atom represented by X C for example, a fluorine atom, a chlorine atom, a bromine atom, an iodine atom. Preferably it is a chlorine atom.
  • the reaction for converting the compound represented by the general formula (7) to the compound represented by the general formula (13) is the same as the reaction represented by the general formula (9a) in the reaction formula-2.
  • the reaction can be carried out under the same reaction conditions as those leading to the compounds represented.
  • the obtained compound represented by the general formula (13) can be converted into a salt such as hydrochloride, sulfate, p-toluenesulfonate, and the like, if necessary, using a known salt formation method.
  • a salt By using a salt, the phenylenediamine compound represented by the general formula (13), which is generally unstable, can be stably obtained.
  • reaction of the compound represented by the general formula (13) or a salt thereof and the compound represented by the general formula (14) can be performed in a suitable solvent.
  • the solvent examples include ethers such as dioxane, tetrahydrofuran, diethyl ether, diethylene glycol dimethyl ether, and ethylene glycol dimethyl ether; aromatic hydrocarbons such as benzene, toluene, and xylene; halogenated compounds such as dichloromethane, dichloroethane, chloroform, and carbon tetrachloride. Hydrocarbons; ketones such as acetone and methyl ethyl ketone; polar solvents such as dimethylformamide (DMF), dimethylacetamide (DMA), dimethyl sulfoxide (DMSO), hexamethylphosphoric triamide, acetonitrile, and mixed solvents thereof It is done.
  • Aromatic hydrocarbons such as toluene and xylene are preferred.
  • the amount of the compound represented by the general formula (14) to be used is usually 0.5 to 1.5 mol, preferably 0.7 to 1.3 mol, relative to 1 mol of the compound represented by the general formula (13). Mol, more preferably 0.8 to 1.2 mol.
  • the above reaction is usually carried out at 0 to 150 ° C., preferably 0 to 120 ° C., and is usually completed in 1 to 80 hours.
  • the compounds represented by the general formulas (2f) and (2g) can be produced, for example, by the process described in Reaction Scheme-4.
  • the compounds represented by the general formulas (2h) and (2i) can be produced, for example, by the process described in Reaction Scheme-5.
  • a known isolation operation for example, filtration, concentration, extraction, etc.
  • a known purification means for example, column chromatography, recrystallization, etc.
  • Example 1 Synthesis of 5-fluoro-N-methyl-2-nitroaniline To a methanol solution (200 mL) of 46.7 g (0.29 mol) of 2,4-difluoronitrobenzene, 61 mL of an aqueous solution of 40% methylamine under ice-cooling ( 0.71 mol) was added dropwise, followed by stirring at the same temperature for 1 hour. The reaction solution was poured into ice water, and the precipitated crystals were collected by filtration and washed with water. The obtained crystals were dried at 50 ° C. to obtain 47.6 g (yield 95%) of the title compound as a yellow powder.
  • Example 3 To a solution of 510 mg (3 mmol) of 5-fluoro-N-methyl-2-nitroaniline in N, N-dimethylformamide (5 mL), 0.93 mL (9 mmol) of benzyl alcohol and 1.24 g (9 mmol) of potassium carbonate. And stirred at 60-70 ° C. for 8 hours. After cooling the reaction solution, water was added and the precipitated crystals were collected by filtration. The obtained crystals were washed with water and dried at 50 ° C. to obtain 680 mg (yield 88%) of 5-benzyloxy-N-methyl-2-nitroaniline as an orange powder.
  • Example 4 To a solution of benzyl alcohol 0.93 mL (9 mmol) in N, N-dimethylformamide (5 mL) was added 865 mg (9 mmol) of sodium t-butoxide, and after stirring at room temperature for 30 minutes, 5-fluoro-N-methyl- 510 mg (3 mmol) of 2-nitroaniline was added and stirred at room temperature for 3 hours. Water was added to the reaction solution, and the precipitated crystals were collected by filtration. The obtained crystals were washed with water and dried at 50 ° C. to obtain 710 mg (yield 92%) of 5-benzyloxy-N-methyl-2-nitroaniline as an orange powder.
  • Example 5 To a toluene solution (50 mL) of 5.0 g (31.4 mmol) of 2,4-difluoronitrobenzene, 8.2 mL (94.2 mmol) of a 40% methylamine aqueous solution was added dropwise under ice cooling, and then 35-40 Stir at 0 ° C. for 2 hours. Water was added to the reaction solution, extracted with toluene, and washed with water. To the obtained organic layer, 6.5 mL (62.8 mmol) of benzyl alcohol, 1.0 g (3.1 mmol) of tetrabutylammonium bromide and 5.2 g (37.6 mmol) of potassium carbonate were added and heated for 4 hours. Refluxed.
  • Example 6 To a toluene solution (500 mL) of 50.0 g (0.31 mol) of 2,4-difluoronitrobenzene, 82 mL (0.94 mol) of a 40% methylamine aqueous solution was added dropwise under ice cooling, and then at 35-40 ° C. Stir for 2 hours. Water was added to the reaction solution, extracted with toluene, and washed with water. The obtained organic layer was concentrated under reduced pressure to about half.
  • Benzyl alcohol 65 mL (0.63 mol), tetrabutylammonium hydrogen sulfate 10.7 g (31.5 mmol), potassium carbonate 65.2 g (0.47 mol), water (5 mL) were added to the resulting solution, The mixture was heated to reflux for 4 hours. After cooling the reaction solution, water (250 mL) was added and stirred at 70 ° C. for 1 hour. The mixture was stirred for 30 minutes under ice cooling, and the precipitated crystals were collected by filtration. The obtained crystals were washed with water, added to methanol (500 mL), heated under reflux for 30 minutes, and stirred at 10 ° C. or lower for 1 hour.
  • Example 10 Of 8-benzyloxy-1-methyl-1,5-dihydrobenzo [b] [1,4] diazepine-2,4-dione 1.01 g (3.4 mmol) of N, N-dimethylformamide (5 mL) To the solution, 330 mg (3.43 mmol) of sodium t-butoxide was added under ice cooling, and after stirring for 30 minutes under ice cooling, 0.51 mL (3.69 mmol) of diethyl sulfate was added, followed by stirring for 6 hours under ice cooling. did. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate (20 mL).
  • Example 14 Synthesis of 5-benzyloxy-N 1 -methylbenzene-1,2-diamine hydrochloride To a suspension of 20 g (77.4 mmol) of 5-benzyloxy-N-methyl-2-nitroaniline in toluene (300 mL) 2.15 g of 5% platinum carbon (water content 53.1%) was added, and catalytic hydrogenation was performed under 4 atm. The reaction solution was filtered to remove the catalyst, and the catalyst was washed with 2-propanol (40 mL) and combined with the previous filtrate. Concentrated hydrochloric acid (6.6 mL, 77.4 mmol) was added to the mixture under ice-cooling, and the mixture was stirred at the same temperature for 30 minutes.
  • the obtained crystals were washed with water, added to methanol (180 mL), and heated to reflux. The mixture was cooled, stirred at 10 ° C. or lower for 30 minutes, and the precipitated crystals were collected by filtration. The obtained crystals were washed with methanol (36 mL) and dried at 60 ° C. to give 18.3 g (yield 83%) of the title compound as a white powder.
  • the reaction was stirred at 10-20 ° C. for 4 hours. Water (42 mL) was added to the reaction mixture, and the mixture was stirred at 10 ° C. or lower for 30 minutes, and the precipitated crystals were collected by filtration. The crystals were added to methanol (60 mL), heated to reflux, and stirred at 10 ° C. or lower for 30 minutes. The crystals were collected by filtration, washed with methanol, and dried at 60 ° C. to give 5.90 g (yield 91%) of the title compound as a white powder.
  • Example 23 1-ethyl-7-benzyloxy-3,3,5-trimethyl-1,5-dihydrobenzo [b] [1,4] diazepine-2,4-dione 39.8 g (113 mmol) of methanol (400 mL) To the solution, 4.00 g of 20% palladium hydroxide carbon was added, and catalytic hydrogenation was performed at room temperature and normal pressure. The reaction solution was filtered to remove the catalyst, and then methanol was distilled off. Ethanol (120 mL) was added to the resulting residue and stirred with heating. After confirming dissolution, water (40 mL) was added and heated again.
  • Example 24 Synthesis of 1-butyl-7-hydroxy-3,3,5-trimethyl-1,5-dihydrobenzo [b] [1,4] diazepine-2,4-dione Using appropriate starting materials, Example 22 and The title compound was synthesized in the same manner.
  • Example 25 Synthesis of 7-hydroxy-1-isopentyl-3,3,5-trimethyl-1,5-dihydrobenzo [b] [1,4] diazepine-2,4-dione
  • Example 22 was prepared using appropriate starting materials and The title compound was synthesized in the same manner.
  • Example 28 1-Ethyl-7-hydroxy-5-methyl-1,5-dihydrobenzo [b] [1,4] diazepine-2,4-dione (1-Ethyl-7-hydroxy-5-methyl-1,5- Synthesis of dihydro-benzo [b] [1,4] diazepine-2,4-dione)
  • the title compound was synthesized in the same manner as in Example 23 using an appropriate starting material.
  • Example 30 Synthesis of 5-benzyloxy-N-isobutyl-2-nitroaniline To a toluene solution (40 mL) of 2,4-difluoronitrobenzene 8.0 g (50.3 mmol) under ice-cooling, 25 mL (121 mmol) of isobutylamine After dropwise addition, the mixture was stirred at 35-40 ° C. for 2 hours. Water was added to the reaction solution, extracted with toluene, washed with water, and the obtained organic layer was concentrated to about half volume under reduced pressure (the concentrated solution contains a crude product of 5-fluoro-N-isobutyl-2-nitroaniline.
  • Example 31 Synthesis of 5-benzyloxy-N 1 -ethylbenzene-1,2-diamine hydrochloride The title compound was synthesized in the same manner as in Example 14 using appropriate starting materials.
  • Example 32 Synthesis of 5-benzyloxy-N 1 -isobutylbenzene-1,2-diamine hydrochloride The title compound was synthesized in the same manner as in Example 14 using appropriate starting materials.
  • Example 37 Synthesis of 1,5-diethyl-7-hydroxy-3,3-dimethyl-1,5-dihydrobenzo [b] [1,4] diazepine-2,4-dione
  • Example 23 was prepared using appropriate starting materials and The title compound was synthesized in the same manner.
  • Example 39 Synthesis of 3-fluoro-N-methyl-2-nitroaniline To a methanol solution (39.5 mL) of 7.90 g (49.7 mmol) of 2,6-difluoronitrobenzene, 40% methylamine methanol under ice-cooling After dropwise addition of 12.2 mL (119 mmol) of the solution, the mixture was stirred at the same temperature for 0.5 hour and at room temperature for 3 hours. The reaction solution was poured into ice water, and the precipitated crystals were collected by filtration and washed with water. The obtained crystals were dried at 50 ° C. to obtain 7.84 g (yield 93%) of the title compound as a red powder.
  • Example 40 Synthesis of 3-benzyloxy-N-methyl-2-nitroaniline To a toluene solution (39 mL) of 7.84 g (46.1 mmol) of 3-fluoro-N-methyl-2-nitroaniline, 9.54 mL ( 92.2 mmol), 1.49 g (4.62 mmol) of tetrabutylammonium bromide and 7.64 g (55.3 mmol) of potassium carbonate were added, and the mixture was heated to reflux for 6 hours. After cooling the reaction solution, water (39 mL) was added and extracted with toluene.
  • Example 41 Synthesis of 3-benzyloxy-N 1 -methylbenzene-1,2-diamine hydrochloride Suspension of 7.19 g (27.8 mmol) of 3-benzyloxy-N-methyl-2-nitroaniline in toluene (80 mL) To the liquid, 0.80 g (dry) of 5% platinum carbon was added, and catalytic hydrogenation was performed under normal pressure. The reaction solution was filtered to remove the catalyst, the catalyst was washed with toluene (10 mL), and the washing solution was combined with the previous filtrate. To the mixed solution, 28 mL (28.0 mmol) of 1N hydrochloric acid ethanol solution was added under ice cooling, and the mixture was stirred at the same temperature for 30 minutes.
  • Example 44 Synthesis of 5-ethyl-6-hydroxy-1,3,3-trimethyl-1,5-dihydrobenzo [b] [1,4] diazepine-2,4-dione
  • Example 23 was prepared using appropriate starting materials and The title compound was synthesized in the same manner.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PCT/JP2010/064040 2009-08-21 2010-08-20 ベンゾ［ｂ］［１，４］ジアゼピン－２，４－ジオン化合物の製造方法 WO2011021676A1 (ja)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CA2771136A CA2771136A1 (en) 2009-08-21 2010-08-20 Process for producing benzo[b][1,4]diazepine-2,4-dione compound
BR112012003871A BR112012003871A2 (pt) 2009-08-21 2010-08-20 processo para a produção de composto de benzo[b][1,4]diazepina-2,4-diona
US13/391,468 US8796447B2 (en) 2009-08-21 2010-08-20 Process for producing benzo[B][1,4]diazepine-2,4-dione compound
RU2012110566/04A RU2553676C2 (ru) 2009-08-21 2010-08-20 СПОСОБ ПОЛУЧЕНИЯ ПРОИЗВОДНОГО БЕНЗО[b][1,4]ДИАЗЕПИН-2,4-ДИОНА
CN201080037096.9A CN102639512B (zh) 2009-08-21 2010-08-20 苯并[b][1,4]二氮杂*-2,4-二酮化合物的制备方法
IN986DEN2012 IN2012DN00986A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2009-08-21 2010-08-20
JP2011527709A JP5649577B2 (ja) 2009-08-21 2010-08-20 ベンゾ［ｂ］［１，４］ジアゼピン−２，４−ジオン化合物の製造方法
EP10810017A EP2468733A4 (en) 2009-08-21 2010-08-20 PROCESS FOR PRODUCING BENZO [B] [1,4] DIAZEPINE-2,4-DIONE COMPOUND
IL217855A IL217855A (en) 2009-08-21 2012-01-31 Benzo Compounds [b] [4,1] Diazepine-4,2-Deon and Process for their Preparation
US14/202,793 US8940889B2 (en) 2009-08-21 2014-03-10 Process for producing benzo [b] [1,4] diazepine-2,4-dione compound

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23598809P 2009-08-21 2009-08-21
US61/235988 2009-08-21

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/391,468 A-371-Of-International US8796447B2 (en) 2009-08-21 2010-08-20 Process for producing benzo[B][1,4]diazepine-2,4-dione compound
US14/202,793 Continuation US8940889B2 (en) 2009-08-21 2014-03-10 Process for producing benzo [b] [1,4] diazepine-2,4-dione compound

Publications (1)

Publication Number Publication Date
WO2011021676A1 true WO2011021676A1 (ja) 2011-02-24

Family

ID=43607124

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2010/064040 WO2011021676A1 (ja) 2009-08-21 2010-08-20 ベンゾ［ｂ］［１，４］ジアゼピン－２，４－ジオン化合物の製造方法

Country Status (11)

Country Link
US (2) US8796447B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2468733A4 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP5649577B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20120065360A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN102639512B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112012003871A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2771136A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL217855A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2012DN00986A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2553676C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2011021676A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023210741A1 (ja) 2022-04-28 2023-11-02 第一三共株式会社 ベンゾトリアゾール化合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1210809A (en) * 1966-12-14 1970-11-04 Roussel Uclaf Benzodiazepine derivatives
WO2001077143A2 (en) * 2000-04-05 2001-10-18 Glaxo Group Limited Process for the preparation of 3-amino-1, 5-benzodiazepine derivatives
WO2007026959A2 (en) * 2005-08-31 2007-03-08 Otsuka Pharmaceutical Co., Ltd. Derivatives of 4-piperazin-1-yl-4-benz0 [b] thiophene suitable for the treatment of cns disorders
WO2009104819A1 (en) 2008-02-22 2009-08-27 Otsuka Pharmaceutical Co., Ltd. Benzodiazepine compound and pharmaceutical composition

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1005A (en) * 1838-11-12 Ing and heating booms and other apabtments beqtjibing abtrficial
US3133056A (en) 1961-05-15 1964-05-12 May & Baker Ltd N-phenylpiperazine derivatives of tetrahydrobenzodiazepines
US3984398A (en) * 1966-12-14 1976-10-05 Roussel-Uclaf 1,5-Benzodiazepine-2,4-diones
US4001408A (en) 1966-12-14 1977-01-04 Roussel-Uclaf Substituted heterocyclic compounds, processes and composition including those
SU455539A3 (ru) * 1970-11-02 1974-12-30 К.Х.Берингре Зон (Фирма) Способ получени 2-алкокси-5 фенил-4н-3,5-дигидро-1,5-бензодиазепин-4-онов
GB1460936A (en) 1974-10-01 1977-01-06 Beecham Group Ltd Benzodiazepines
NZ187452A (en) 1977-06-10 1980-05-27 Otsuka Pharma Co Ltd N- substituted-aminocarbonylpropoxy-carbostyrils and their preparation
JPS56122356A (en) 1980-02-29 1981-09-25 Otsuka Pharmaceut Co Ltd Carbostyril derivative
JP2753622B2 (ja) 1988-05-02 1998-05-20 大塚製薬株式会社 カルボスチリル誘導体
JPH0296133A (ja) 1988-10-01 1990-04-06 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
BR9200951A (pt) 1991-03-21 1992-11-17 Hoffmann La Roche Compostos, processo para sua producao,preparacoes farmaceuticas e uso
AU653060B2 (en) 1991-08-23 1994-09-15 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivative and platelet agglutination inhibitor
PE27497A1 (es) 1994-04-15 1997-08-07 Glaxo Inc Derivados de 1,5 benzodiazepina
US5691331A (en) 1995-06-07 1997-11-25 Merck & Co., Inc. N-(2,4-Dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3yl) -3- amides
US5700797A (en) 1995-06-07 1997-12-23 Merck & Co, Inc. N-(2,4-dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3-yl)-3-amides
TW338037B (en) 1995-10-05 1998-08-11 Otsuka Pharma Co Ltd Carbostyril derivatives possessing platelet aggregation inhibitory activity, antithrombotic activity, intima thinkening, inhibitory activity and phosphoriesterase inhibitory activity, their preparation and pharmaceutical composition
AU6895000A (en) 1999-08-09 2001-03-05 Merck & Co., Inc. Antiarrhythmic compounds
US6949542B2 (en) 2002-02-06 2005-09-27 Hoffman-La Roche Inc. Dihydro-benzo[b][1,4]diazepin-2-one derivatives
US7772433B2 (en) 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
EA011087B1 (ru) 2002-12-20 2008-12-30 Эмджен Инк. Соединения и фармацевтические композиции для лечения воспалительных заболеваний
TWI481601B (zh) * 2009-08-21 2015-04-21 Otsuka Pharma Co Ltd 含氮化合物及藥學組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1210809A (en) * 1966-12-14 1970-11-04 Roussel Uclaf Benzodiazepine derivatives
WO2001077143A2 (en) * 2000-04-05 2001-10-18 Glaxo Group Limited Process for the preparation of 3-amino-1, 5-benzodiazepine derivatives
WO2007026959A2 (en) * 2005-08-31 2007-03-08 Otsuka Pharmaceutical Co., Ltd. Derivatives of 4-piperazin-1-yl-4-benz0 [b] thiophene suitable for the treatment of cns disorders
WO2009104819A1 (en) 2008-02-22 2009-08-27 Otsuka Pharmaceutical Co., Ltd. Benzodiazepine compound and pharmaceutical composition

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
AM. J. CARDIOL., vol. 72, 1993, pages B44 - B49
CIRCULATION, vol. 114, 2006, pages 119 - 123
CRIC. RES., vol. 73, 1993, pages 1061 - 1076
CRIC. RES., vol. 80, 1997, pages 572 - 579
J. PHYSIOL., vol. 491, 1996, pages 31 - 50
NATURE REVIEWS DRUG DISCOVERY, vol. 4, 2005, pages 899 - 910
NATURE REVIEWS DRUG DISCOVERY, vol. 5, 2006, pages 1034 - 1049
NATURE, vol. 374, 1995, pages 135 - 141
See also references of EP2468733A4
THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol. 285, 2001, pages 2370 - 2375
TRENDS PHARMACOL. SOC., vol. 22, 2001, pages 240 - 246

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023210741A1 (ja) 2022-04-28 2023-11-02 第一三共株式会社 ベンゾトリアゾール化合物

Also Published As

Publication number Publication date
IL217855A0 (en) 2012-03-29
BR112012003871A2 (pt) 2015-09-08
CN102639512A (zh) 2012-08-15
CN102639512B (zh) 2015-12-09
RU2012110566A (ru) 2013-09-27
US8940889B2 (en) 2015-01-27
RU2553676C2 (ru) 2015-06-20
JP5649577B2 (ja) 2015-01-07
US8796447B2 (en) 2014-08-05
US20120149899A1 (en) 2012-06-14
CA2771136A1 (en) 2011-02-24
IL217855A (en) 2016-08-31
IN2012DN00986A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-04-10
US20140194621A1 (en) 2014-07-10
EP2468733A1 (en) 2012-06-27
JPWO2011021676A1 (ja) 2013-01-24
EP2468733A4 (en) 2013-02-06
KR20120065360A (ko) 2012-06-20

Similar Documents

Publication Publication Date Title
US7452888B2 (en) Quinoline derivatives and their use as 5-ht6 ligands
US8765945B2 (en) Processes of synthesizing dihydropyridophthalazinone derivatives
US9856215B2 (en) Preparation method of Nintedanib
JPH04342571A (ja) アザサイクリック化合物
HU195961B (en) Process for producing substituted 2-/1h/-quinolone derivatives
Stadlbauer et al. Halogenation reactions in position 3 of quinoline-2, 4-dione systems by electrophilic substitution and halogen exchange
CN101462974B (zh) 5-氨基酮戊酸盐酸盐的合成方法
US5416221A (en) Carbazolone derivatives
HU189747B (en) Process for producing 1-phenyl-2/1h,3h/-indolone derivatives and pharmaceutical compositions containing them
AU2009221091B2 (en) Process for preparing enantiomerically pure indolopyridines
JP5649577B2 (ja) ベンゾ［ｂ］［１，４］ジアゼピン−２，４−ジオン化合物の製造方法
US4012513A (en) Indole derivatives for providing analgesic and anti-inflammatory effects
JPS61286367A (ja) ベンズアゼピン誘導体
US7126009B2 (en) Palladium catalyzed indolization of 2-bromo or chloroanilines
JP4789483B2 (ja) ４−ニトロイミダゾール化合物の製造法
JP5198562B2 (ja) 置換−３−アミノピラゾールの合成
IE59937B1 (en) Quinazolinediones and pyridopyrimidinediones
Bertelli et al. 1‐(1, 2, 3‐triazol‐4‐yl)‐benzimidazolones, a new series of heterocyclic derivatives
Bänziger et al. Intriguing Influence of the Solvent on the Regioselectivity of Sulfoxide Thermolysis in β‐Amino‐α‐sulfinyl Esters
WO2000055116A1 (fr) Procede de production de derives d'acide 5-amino-8- alkylquinolo necarboxylique, et produits intermediaires intervenant dans la production
EP0444851A2 (en) Hexahydrobenz[CD]indoles and processes for preparation thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080037096.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10810017

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2011527709

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 217855

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 986/DELNP/2012

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2771136

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13391468

Country of ref document: US

REEP Request for entry into the european phase

Ref document number: 2010810017

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010810017

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20127007170

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012110566

Country of ref document: RU

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012003871

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012003871

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120222